{"schema_version":"1.0","type":"article","title":"How Mid-Sized Biotechs Are Turning Blockbuster Drugs From Dreams Into Cash Flow","url":"https://drugnews.com.tw/articles/2026-05-22-mid-size-biotech-blockbuster-cashflow-en.html","markdown_url":"https://drugnews.com.tw/articles/2026-05-22-mid-size-biotech-blockbuster-cashflow-en.md","lang":"en","date":"2026-05-22","publish_at":"2026-05-22T10:30:00+08:00","updated_at":"2026-05-22","category":"商業分析系列","topic":"商業分析系列","tags":["Business Analysis","Obesity medicine","CNS","Regulatory risk","Biotech business analysis","Drug development"],"summary":"A Drugnews English brief on How Mid-Sized Biotechs Are Turning Blockbuster Drugs From Dreams Into Cash Flow, focusing on obesity medicine, clinical evidence, company strategy, business development, and biotech capital-market implications.","key_points":[],"facts":[],"sections":["Core Thesis","Why It Matters","Reading Framework","What To Watch Next","Original Chinese Edition"],"references":[],"images":[],"cover_image":"https://drugnews.com.tw/assets/english/drugnews-english-analysis-cover.png","publisher":{"name":"Drugnews｜藥時事","url":"https://drugnews.com.tw/","profile":"https://drugnews.com.tw/brand-profile.json"},"citation":"Drugnews｜藥時事（2026-05-22）。How Mid-Sized Biotechs Are Turning Blockbuster Drugs From Dreams Into Cash Flow。https://drugnews.com.tw/articles/2026-05-22-mid-size-biotech-blockbuster-cashflow-en.html","disclaimer":"This article is intended for industry research and knowledge sharing only. It does not constitute investment, medical, fundraising, or individual stock advice.","translations":{"zh-Hant":"2026-05-22-mid-size-biotech-blockbuster-cashflow.html"},"relationship":"independent_editorial","disclosure_url":"https://drugnews.com.tw/policy/"}